Over the past three decades, cancer vaccines have evolved from experimental concepts to transformative tools in oncology. From early preventive breakthroughs with hepatitis B and HPV vaccines to cutting-edge mRNA platforms and neoantigen-targeting approaches, these innovations are reshaping cancer prevention and treatment. While challenges such as tumor heterogeneity and immune suppression remain, recent advances in personalized medicine, combination therapies, and delivery systems are unlocking the full potential of cancer vaccines. This article examines the milestones, current progress, and future opportunities in this dynamic field, offering hope for more effective and accessible cancer care.
Harnessing the Immune System to Combat Cancer
Cancer vaccines represent one of the most ambitious pursuits in the field of oncology — a quest to harness the power of the immune system to prevent and treat one of the most formidable classes of diseases. Over the past few decades, the concept of cancer vaccines has evolved from a novel and largely experimental idea to a promising pillar in cancer immunotherapy. This progress reflects a broader transformation in biomedical research, driven by advances in immunology, molecular biology, and biotechnology.
The journey of cancer vaccines is one of perseverance and innovation. Early attempts were rooted in the pioneering work of William Coley in the late 19th century, who used bacterial toxins to stimulate immune responses against tumors. These rudimentary experiments laid the foundation for a field that has since grown into a sophisticated arena of medicine, encompassing preventive vaccines like those for hepatitis B and human papillomavirus (HPV) and therapeutic approaches designed to combat existing malignancies.
Today, cancer vaccines are positioned at the forefront of personalized medicine, with evolving technologies, such as mRNA platforms and neoantigen targeting, offering new hope for patients. The success of the COVID-19 mRNA vaccines has further propelled interest in adapting similar technologies for oncology, marking a new era of innovation. Despite the significant progress, challenges persist, including tumor heterogeneity, immune suppression, and the complexities of vaccine development and delivery.
The Historical Evolution of Cancer Vaccines
The concept of leveraging the immune system to combat cancer has roots stretching back to the late 19th century, when William Coley, often referred to as the "Father of Immunotherapy," pioneered the use of bacterial toxins to treat sarcomas. By injecting a mixture of inactivated bacteria, Coley sought to provoke a strong immune response capable of attacking tumors. While these early experiments lacked the scientific rigor applied to such research today, they laid the foundation for the modern idea that the immune system could be harnessed to fight cancer.1
The first transformative advancements in cancer vaccine development emerged with preventive approaches targeting cancers linked to infectious agents. The approval of the hepatitis B vaccine in 1981 marked a pivotal moment, significantly reducing the incidence of liver cancer associated with chronic hepatitis B infection.2 The introduction of the HPV vaccine in 2006 further showcased the power of immunization, dramatically decreasing cervical cancer rates and extending protection to other HPV-associated malignancies, such as head and neck cancers.3 These successes established immunization as a viable strategy for preventing cancer by targeting oncogenic viruses.
Building on the success of preventive vaccines, efforts turned toward developing therapeutic vaccines aimed at treating existing cancers. Early strategies included whole-cell vaccines, which involved irradiating tumor cells to inactivate their replicative potential before reintroducing them to the patient’s immune system. However, these approaches faced significant hurdles, including limited efficacy in overcoming the immunosuppressive environment created by tumors.4 A major breakthrough came in 2010 with the FDA approval of sipuleucel-T (Provenge), a dendritic cell-based vaccine designed for metastatic, castration-resistant prostate cancer. This therapy marked the first therapeutic cancer vaccine to demonstrate a survival benefit, providing proof of concept that priming the immune system to recognize cancer antigens could lead to tangible clinical outcomes.5
Recently, the focus has shifted toward personalized approaches, exemplified by neoantigen vaccines. These vaccines target mutations unique to an individual's tumor, addressing the inherent challenges of tumor heterogeneity. Advances in next-generation sequencing (NGS) have made it possible to rapidly identify neoantigens, enabling the development of tailored vaccines that elicit highly specific immune responses.6 Meanwhile, the COVID-19 pandemic catalyzed progress in mRNA vaccine platforms, showcasing their rapid development timelines and scalability. Researchers have since adapted this technology to cancer vaccines, yielding promising early clinical results in cancers such as melanoma.7 These advancements illustrate the potential of modern cancer vaccines to redefine treatment paradigms, building on a legacy of innovation and perseverance.
Preventive and Therapeutic Approaches in Cancer Immunology
Cancer vaccines can be categorized into preventive (prophylactic) and therapeutic types, on the basis of which stage of cancer development they target. While preventive vaccines aim to reduce the risk of cancer by addressing infections linked to malignancies, therapeutic vaccines are designed to treat existing cancers by stimulating the immune system to attack tumor cells. Over time, these approaches have evolved through the development of innovative platforms and strategies, shaping the current landscape of cancer immunotherapy.
Preventive vaccines represent some of the earliest successes in cancer immunology. The hepatitis B vaccine, approved in 1981, was a pivotal milestone, significantly reducing liver cancer incidence by preventing chronic hepatitis B infections.2 Similarly, the introduction of the HPV vaccine in 2006 transformed cervical cancer prevention and extended protection to other HPV-associated malignancies, such as head and neck cancers.3 These vaccines work by stimulating the immune system to produce antibodies that neutralize oncogenic viruses before they can infect cells, providing a blueprint for future preventive strategies targeting other carcinogenic pathogens.
Therapeutic vaccines, on the other hand, are designed to combat existing cancers by generating immune responses against tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). Early therapeutic approaches often utilized whole-cell vaccines derived from autologous (patient-derived) or allogeneic (donor-derived) tumor cells. These vaccines present a broad array of antigens to the immune system, though their nonspecific nature has sometimes limited their efficacy. For example, GVAX, an allogeneic cancer vaccine secreting granulocyte-macrophage colony-stimulating factor (GM-CSF), showed modest benefits in pancreatic cancer trials, highlighting the need for more refined approaches.8
Peptide-based vaccines offered a more targeted strategy by using short amino acid sequences derived from TAAs or TSAs to activate T cells. These vaccines demonstrated high specificity but faced challenges related to the variability of patients’ major histocompatibility complex (MHC) molecules, which are essential for antigen presentation. For instance, the MAGE-A3 peptide vaccine, developed for melanoma and non-small-cell lung cancer, initially showed promise but failed to demonstrate survival benefits in later-phase trials, underscoring the complexities of achieving durable clinical outcomes.9
Dendritic cell vaccines, such as sipuleucel-T (Provenge), took a more innovative approach by leveraging the antigen-presenting capabilities of dendritic cells. By harvesting dendritic cells from patients, loading them with tumor antigens ex vivo, and re-infusing them, these vaccines directly primed T cells to recognize and attack cancer cells. The success of sipuleucel-T in extending survival in metastatic prostate cancer provided a significant validation of dendritic cell-based strategies.5
The emergence of nucleic acid–based vaccines, including DNA and mRNA platforms, has opened new frontiers in cancer immunotherapy. These vaccines deliver genetic instructions for tumor antigens directly into the patient’s cells, enabling in situ antigen production and immune activation. mRNA vaccines have gained particular momentum owing to their rapid manufacturing capabilities and flexibility. Early clinical trials of mRNA vaccines targeting neoantigens in melanoma have shown encouraging results, demonstrating their potential to elicit robust immune responses.7
Oncolytic virus–based vaccines add another layer of innovation by using engineered viruses that selectively infect and destroy cancer cells while stimulating anti-tumor immunity. Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus expressing GM-CSF, exemplifies this approach. Approved for melanoma, T-VEC has demonstrated efficacy as both a standalone therapy and in combination with other immunotherapies, highlighting the versatility of oncolytic viruses in cancer treatment.10
By building on these successes, future innovations are poised to further enhance the efficacy and accessibility of cancer vaccines, reshaping the landscape of cancer therapy.
How Cancer Vaccines Work to Defeat Tumors
Cancer vaccines are designed to stimulate the immune system to recognize and eliminate tumor cells, overcoming the natural barriers that allow cancer to evade detection. This process relies on a detailed understanding of immunology and can be broken down into three interconnected steps: antigen presentation, immune activation, and tumor destruction. Together, these steps form the backbone of how cancer vaccines function, enabling targeted immune responses.
The process begins with the delivery of antigens, which are molecules recognized as foreign by the immune system. These antigens can be TAAs overexpressed in cancer cells but also found in normal tissues, or TSAs, which arise from mutations unique to tumor cells.7 Cancer vaccines use various platforms, including peptides, nucleic acids, and whole cells, to deliver these antigens. Once introduced into the body, APCs, such as dendritic cells, process the antigens and present them on their surface using MHC molecules. This antigen presentation is crucial for initiating an adaptive immune response, linking the innate and adaptive immune systems.11
Following antigen presentation, the immune response is activated through the engagement of helper T cells (CD4+ T cells) and cytotoxic T lymphocytes (CTLs or CD8+ T cells). Helper T cells recognize antigens on MHC class II molecules and release cytokines that orchestrate a coordinated immune attack. These cytokines play a vital role in amplifying and maintaining the activity of cytotoxic T cells, which are the primary effectors of tumor destruction.12 Cytotoxic T cells, on the other hand, recognize antigens presented on MHC class I molecules found on tumor cells. Once activated, these T cells release cytotoxic proteins such as perforins and granzymes, inducing apoptosis in cancer cells and effectively reducing tumor burden.13
To enhance immune activation, many cancer vaccines incorporate adjuvants — substances designed to boost the immune response. Adjuvants like GM-CSF or Toll-like receptor (TLR) agonists recruit and activate APCs, ensuring that antigens are effectively processed and presented to T cells.14 These adjuvants play a critical role in amplifying the effectiveness of cancer vaccines, particularly in immunosuppressive tumor environments.
The culmination of these steps is tumor destruction, where activated CTLs infiltrate the tumor microenvironment (TME) and specifically target cancer cells expressing the delivered antigens. Through the release of cytotoxic molecules, CTLs induce apoptosis in tumor cells, reducing their growth and spread. Beyond immediate tumor clearance, the immune system’s memory function ensures sustained protection, significantly lowering the risk of cancer recurrence.15
Despite these advancements, tumors have evolved sophisticated mechanisms to evade immune detection, posing a significant challenge to cancer vaccine efficacy. Tumors often create an immunosuppressive microenvironment by recruiting regulatory T (Treg) cells and myeloid-derived suppressor cells (MDSCs) and secreting cytokines like interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which inhibit T cell activity. Additionally, tumors can downregulate MHC molecule expression, further evading recognition by CTLs.16
To overcome these barriers, cancer vaccines are increasingly paired with immune checkpoint inhibitors, such as anti-PD-1/PD-L1 or anti-CTLA-4 antibodies. These inhibitors release the inhibition on T cells, restoring their ability to attack tumors effectively. Combination therapies have shown promising results in enhancing vaccine efficacy and overcoming tumor immune evasion, marking a critical step forward in cancer immunotherapy.17
Challenges in Developing Effective Cancer Vaccines
Despite significant advancements in cancer vaccine research, several hurdles limit their efficacy, accessibility, and widespread adoption. These challenges span biological, technical, and logistical domains, underscoring the complexity of developing effective cancer vaccines.
One of the most significant obstacles is tumor heterogeneity. Tumors exhibit substantial genetic, molecular, and phenotypic variability, both within individual tumors (intra-tumoral heterogeneity) and across patients with the same type of cancer (inter-tumoral heterogeneity). This diversity makes it difficult to identify universal antigens suitable for targeting by vaccines.18
Personalized approaches, such as neoantigen-based vaccines, aim to address this challenge by tailoring the vaccine to a patient’s unique tumor profile. However, these strategies are resource-intensive, requiring complex sequencing and manufacturing processes that remain logistically demanding. Adding to this complexity are the sophisticated mechanisms tumors have evolved to evade immune detection. Tumor cells can downregulate the expression of MHC molecules, reducing their visibility to T cells. At the same time, they secrete immunosuppressive cytokines like TGF-β and IL-10, which inhibit T cell activation and proliferation.16 The TME exacerbates this suppression by recruiting Treg cells and MDSCs, further dampening anti-tumor immune responses. To counter these mechanisms, combination therapies integrating cancer vaccines with immune checkpoint inhibitors have emerged as a promising strategy, unlocking T cells and restoring their ability to recognize and attack tumor cells.
Balancing safety and efficacy presents another challenge. While cancer vaccines aim to elicit robust immune responses, they must avoid triggering autoimmunity or other adverse effects. TAAs, which are overexpressed in cancer cells but also found in healthy tissues, pose a particular risk of off-target effects. For instance, targeting shared antigens like HER2/neu or WT1 can inadvertently harm normal cells if the immune response is not tightly regulated.19 Achieving durable responses is especially difficult in patients with advanced cancers, as their immune systems are often compromised. Strategies to enhance vaccine efficacy, such as incorporating potent adjuvants or combining vaccines with other immunotherapies, are actively being explored to address these limitations.
Delivery challenges further complicate cancer vaccine development. Traditional platforms, such as peptide-based or whole-cell vaccines, often struggle to elicit strong immune responses without additional support. Nucleic acid-based platforms, like mRNA vaccines, offer greater flexibility and scalability but face technical hurdles related to stability and efficient delivery to APCs.7 Recent innovations in delivery systems, such as lipid nanoparticles for mRNA vaccines and viral vectors for antigen transport, show promise but require further refinement to maximize safety and effectiveness. Ensuring consistent and reliable manufacturing processes for these advanced platforms remains a critical priority.
The regulatory and manufacturing landscape adds further complexity, particularly for personalized therapies. Developing individualized vaccines involves rapid sequencing, antigen identification, and manufacturing within short timeframes, which can strain existing regulatory frameworks. Scaling production while maintaining quality and consistency is particularly challenging for autologous vaccines like sipuleucel-T (Provenge), where each batch is unique to the patient.5
Clinical trials also face significant barriers. Patient selection criteria often focus on individuals with advanced-stage cancers, where compromised immune systems make it difficult to demonstrate vaccine efficacy. Additionally, the variability in immune responses among patients complicates trial design, requiring long-term follow-up to assess outcomes fully.20 These challenges highlight the need for innovative trial methodologies to evaluate cancer vaccines effectively.
Economic barriers further limit the accessibility of cancer vaccines. High development and manufacturing costs, coupled with complex delivery logistics, have restricted the availability of these therapies, particularly in low- and middle-income countries. For instance, sipuleucel-T faced criticism for its high price despite demonstrating survival benefits in prostate cancer.5 Addressing these cost barriers while ensuring quality will be crucial for expanding access to cancer vaccines globally.
Recent Advances Driving Innovation in Cancer Vaccines
The field of cancer vaccine development has been transformed in recent years by advances in immunology, genomics, and biotechnology. These breakthroughs have not only deepened our understanding of the immune system’s potential but also introduced novel platforms and strategies that are reshaping the landscape of cancer immunotherapy.
One of the most significant advancements lies in neoantigen-based vaccines, which mark a step forward in personalized cancer treatment. Neoantigens, unlike TAAs, are unique to individual tumors, arising from specific mutations within cancer cells. These characteristics make them ideal targets for highly specific immune responses. Advances in NGS and computational modeling have facilitated the rapid identification of neoantigens, enabling the development of tailored vaccines for each patient’s unique tumor profile. Early clinical trials in melanoma have shown robust T cell activation and durable anti-tumor responses, underscoring the potential of this personalized approach to address tumor heterogeneity.6
Parallel to these developments, mRNA vaccine technology has emerged as a versatile platform with applications extending beyond infectious diseases. The global success of mRNA vaccines during the COVID-19 pandemic highlighted their adaptability, scalability, and ability to encode multiple antigens simultaneously. These qualities make mRNA vaccines particularly promising for cancer treatment. Several mRNA-based cancer vaccines are currently in clinical trials, with BioNTech’s individualized vaccine demonstrating potent immune responses against patient-specific neoantigens in early-phase studies.7 This progress signals a new era for cancer vaccines, leveraging the speed and precision of mRNA technology.
Combination therapies have also gained traction as a means to enhance the efficacy of cancer vaccines. Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, release the immune system’s “brakes,” allowing T cells to sustain their attack on tumors. When paired with cancer vaccines, these inhibitors can overcome the immunosuppressive effects of the TME, leading to synergistic outcomes. Studies combining dendritic cell vaccines with ICIs in melanoma patients have demonstrated heightened T cell activation and improved tumor-specific immunity, underscoring the potential of integrated approaches.17,21
Oncolytic virus-based vaccines offer another promising avenue, utilizing engineered viruses to selectively infect and destroy cancer cells while stimulating the immune system. Talimogene laherparepvec (T-VEC), an oncolytic herpes simplex virus expressing GM-CSF, became the first oncolytic virus to receive FDA approval. T-VEC not only lyses tumor cells but also creates a pro-inflammatory environment that enhances immune recognition. Efforts are now focused on combining oncolytic viruses with other immunotherapies, such as ICIs and mRNA vaccines, to amplify their efficacy.10
Adjuvant innovations have further expanded the potential of cancer vaccines by enhancing their immunogenicity. Novel adjuvants, such as Toll-like receptor (TLR) agonists and STING agonists, stimulate innate immune pathways, improving antigen presentation and T cell activation. For instance, a recent study combining a STING agonist with a peptide-based cancer vaccine demonstrated robust anti-tumor responses in preclinical models, highlighting the importance of leveraging innate immunity to complement adaptive responses.22
Effective delivery systems have been critical to maximizing vaccine efficacy. Lipid nanoparticles (LNPs), which gained prominence during the COVID-19 pandemic, have become a cornerstone for delivering mRNA cancer vaccines. Their ability to protect fragile mRNA molecules and efficiently deliver them to antigen-presenting cells has revolutionized vaccine design. Similarly, viral vectors, such as adenoviruses and lentiviruses, are being optimized for high-efficiency antigen delivery while improving safety profiles for clinical applications.23
Recent years have also witnessed significant milestones in clinical trials and regulatory approvals. Sipuleucel-T (Provenge), the first FDA-approved therapeutic cancer vaccine, demonstrated a survival benefit in metastatic prostate cancer, establishing the clinical viability of therapeutic vaccines.5 Moderna’s mRNA-4157/V940, a personalized mRNA vaccine in combination with pembrolizumab, has shown promise in reducing recurrence rates in melanoma compared to ICIs alone.24 Additionally, the PRAME multi-peptide vaccine has advanced to phase II trials, showing potential in early-stage melanoma patients.25
These advancements represent a new frontier in cancer vaccine development, fueled by innovation and interdisciplinary collaboration. By combining novel platforms, adjuvants, and delivery systems with advanced immunotherapy strategies, cancer vaccines are poised to play an increasingly central role in oncology
Emerging Innovations Shaping the Future of Cancer Vaccines
The future of cancer vaccines holds tremendous promise, with new approaches and technologies poised to transform cancer prevention and treatment. These innovations aim to overcome current challenges, enhance efficacy, and make life-saving therapies accessible to more patients worldwide. Several key areas are expected to shape the next generation of cancer vaccines.
Emerging vaccine platforms such as self-amplifying RNA (saRNA) and synthetic long peptides are redefining cancer vaccine design. Self-amplifying RNA offers increased potency by amplifying antigen expression within cells, reducing the required dose while maintaining robust immune responses.26 Similarly, synthetic long peptides, which incorporate multiple epitopes within a single molecule, can activate a broader range of T cells, enhancing their ability to target cancer effectively.27 These platforms exemplify the innovative strides being made to improve vaccine efficacy and scalability.
Artificial intelligence (AI) and precision medicine are becoming indispensable in cancer vaccine development. Machine learning algorithms can analyze genomic and proteomic data to identify neoantigens with high immunogenic potential, accelerating the design of personalized vaccines and optimizing antigen selection.28 Precision medicine complements these efforts by tailoring vaccine strategies to each patient’s unique cancer profile, integrating data on genetic mutations, tumor microenvironment characteristics, and immune status to improve outcomes.
Combination therapies are also gaining momentum as a means to enhance the effectiveness of cancer vaccines. By pairing vaccines with immune checkpoint inhibitors, targeted therapies, or adoptive cell therapies, researchers aim to amplify the immune response and overcome tumor-induced immunosuppression. Emerging studies suggest that bispecific antibodies, which simultaneously engage T cells and tumor antigens, could further boost vaccine efficacy.29 Additionally, therapies that modulate the tumor microenvironment, such as angiogenesis inhibitors or cytokine-based treatments, are showing potential to create more favorable conditions for vaccine-induced immunity.
While personalized vaccines remain a major focus, universal cancer vaccines are also advancing rapidly. These vaccines target common oncogenic drivers, such as KRAS mutations or HER2 overexpression, making them applicable across multiple cancer types. Advances in epitope prediction and delivery systems are helping drive progress toward this ambitious goal, offering the possibility of broad-spectrum cancer prevention and treatment.30
Beyond therapeutic applications, cancer vaccines may play a role in prevention for high-risk populations. For example, individuals with hereditary cancer syndromes, such as BRCA mutations, could benefit from prophylactic vaccines targeting common mutations associated with these cancers.31 Moreover, the concept of using cancer vaccines as adjuvants to other treatments, such as chemotherapy or radiotherapy, is gaining traction. When administered alongside conventional therapies, vaccines could stimulate immune responses that enhance overall treatment efficacy and reduce recurrence rates.20
As cancer vaccine development accelerates, ensuring equitable access to these therapies is critical. High costs and logistical complexities currently limit their availability, particularly in low- and middle-income countries. Efforts to streamline manufacturing processes, reduce costs, and expand global distribution networks will be essential. Collaborative initiatives, such as those led by the Coalition for Epidemic Preparedness Innovations (CEPI) during the COVID-19 pandemic, offer a blueprint for making these advanced therapies accessible to underserved populations.32
Real-world evidence (RWE) is also expected to play an increasing role in evaluating cancer vaccines as they transition into broader clinical use. By integrating advanced digital tools such as wearable devices and real-time monitoring systems, researchers can gather valuable insights into vaccine performance and patient outcomes, enabling continuous improvement.33 This approach will be critical for understanding the long-term safety and efficacy of vaccines and tailoring them to diverse patient populations.
Finally, regulatory innovation will be key to accelerating the approval and availability of cancer vaccines. Adaptive licensing models, which allow for conditional approvals based on early promising data, are being considered by regulatory agencies to expedite access to high-need therapies.34 Collaborative frameworks that integrate early-phase clinical trial data with RWE may further streamline the regulatory process, enabling more rapid deployment of these groundbreaking treatments.
As the field evolves, the integration of innovative platforms, precision medicine, combination strategies, and global collaboration promises to revolutionize cancer vaccine development. By addressing current limitations and advancing scientific frontiers, the next generation of cancer vaccines has the potential to redefine oncology and improve patient outcomes worldwide.
Conclusion: The Transformative Potential of Cancer Vaccines in Oncology
The journey of cancer vaccines over the past three decades underscores a remarkable evolution in biomedical science and immunology. From early experimental approaches to cutting-edge technologies like mRNA vaccines and personalized neoantigen platforms, cancer vaccines have transitioned from conceptual innovation to real-world application. These advancements reflect the resilience and ingenuity of the scientific community, driven by a shared vision to harness the immune system’s power against one of humanity's most formidable diseases.
Cancer vaccines have proven their value not only in preventing virus-induced cancers through prophylactic vaccines like those for hepatitis B and HPV but also in therapeutic settings, as seen with sipuleucel-T and promising clinical trials of mRNA and dendritic cell vaccines. Combination therapies, innovative adjuvants, and new delivery systems continue to push the boundaries of what cancer vaccines can achieve, addressing long-standing challenges like immune evasion, tumor heterogeneity, and delivery inefficiencies.
Looking ahead, the field stands at a pivotal juncture. Advances in AI, precision medicine, and novel platforms, such as self-amplifying RNA and oncolytic viruses, offer exciting opportunities to refine vaccine design and broaden their impact. Efforts to integrate cancer vaccines into combination therapies, target underserved populations, and address regulatory and economic barriers will be critical to ensuring equitable access and global adoption.
By fostering innovation, collaboration, and accessibility, the next generation of cancer vaccines holds the potential to transform oncology and redefine patient care.
Cancer vaccines are more than a scientific achievement; they are a beacon of hope for a future where cancer is no longer a death sentence but a preventable and treatable condition. The ongoing work in this field reaffirms our commitment to improving lives and demonstrates the profound impact of biomedical innovation on human health.
References
Coley, W. B. “Contribution to the Knowledge of Sarcoma.” Annals of Surgery. 14: 199–220 (1891).
Chang, M. H., et al. “Hepatitis B vaccination and prevention of liver cancer in children.” The New England Journal of Medicine. 336: 1855–1859 (1981).
Schiller, J. T., & Lowy, D. R. “Prospects for Preventive HPV Vaccination.” Nature Reviews Microbiology. 4: 518–528 (2006).
Rosenberg, S. A. “A new era for cancer immunotherapy based on the genes that encode cancer antigens.” Immunity. 10: 281–287 (1999).
Kantoff, P. W., et al. “Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.” The New England Journal of Medicine. 363: 411–422 (2010).
Ott, P. A., et al. “An immunogenic personal neoantigen vaccine for patients with melanoma.” Nature. 547: 217–221 (2017).
Sahin, U., et al. “Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.” Nature. 547: 222–226 (2020).
Lutz, E., et al. “Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation.” Cancer Immunology Research. 2: 616–631 (2014).
Vansteenkiste, J., et al. “Antigen-specific cancer immunotherapy using engineered MAGE-A3 synthetic peptide vaccines.” Nature Immunotherapy Advances. 12: 374–385 (2016).
Andtbacka, R. H. I., et al. “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.” Journal of Clinical Oncology. 33: 2780–2788 (2015).
Steinman, R. M. “The dendritic cell system and its role in immunogenicity.” Annual Review of Immunology. 9: 271–296 (1991).
Mescher, M. F., et al. “Signals required for programming effector and memory development by CD8+ T cells.” Immunological Reviews. 211: 81–92 (2006). Russell, J. H., & Ley, T. J. “Lymphocyte-mediated cytotoxicity.” Annual Review of Immunology. 20: 323–370 (2002).
Pulendran, B., & Ahmed, R. “Translating innate immunity into immunological memory: implications for vaccine development.” Cell. 124: 849–863 (2006).
Restifo, N. P., et al. “Adoptive immunotherapy for cancer: harnessing the T cell response.” Nature Reviews Immunology. 12: 269–281 (2012).
Schreiber, R. D., et al. “Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion.” Science. 331: 1565–1570 (2011).
Topalian, S. L., et al. “Safety, activity, and immune correlates of anti–PD-1 antibody in cancer.” The New England Journal of Medicine. 366: 2443–2454 (2012).
Dagogo-Jack, I., & Shaw, A. T. “Tumor heterogeneity and resistance to cancer therapies.” Nature Reviews Clinical Oncology. 15: 81–94 (2018).
Anderson, K. S., et al. “Autoantibody responses to aberrant O-glycopeptide epitopes in ovarian cancer patients.” Cancer Immunology, Immunotherapy. 60: 809–818 (2011).
Mellman, I., et al. “Cancer immunotherapy comes of age.” Nature. 480: 480–489 (2011).
Slingluff, C. L., et al. “Immunologic and clinical outcomes of a randomized Phase II trial of vaccination with melanoma helper peptides and incomplete Freund’s adjuvant, with or without granulocyte-macrophage colony-stimulating factor.” Journal of Clinical Oncology. 29: 2924–2932 (2011).
Li, L., et al. “STING activation boosts innate immunity and reshapes the tumor microenvironment in melanoma.” Science Translational Medicine. 12: eaay2814 (2020).
Roberts, T. C., et al. “Advances in oligonucleotide drug delivery.” Nature Reviews Drug Discovery. 19: 673–694 (2021).
Moderna. “Personalized mRNA-4157/V940 in combination with pembrolizumab for melanoma treatment.” Moderna Clinical Trials. (2023).
Lynch, K. T., et al. “Molecular and immunologic targeting in NTRK fusion-positive cancers.” Journal for ImmunoTherapy of Cancer. 10: e003022 (2022).
Pardi, N., et al. “mRNA vaccines — a new era in vaccinology.” Nature Reviews Drug Discovery. 17: 261–279 (2018).
Kenter, G. G., et al. “Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.” The New England Journal of Medicine. 361: 1838–1847 (2009).
Nguyen, M. L., et al. “Harnessing machine learning to optimize cancer vaccine design.” Trends in Cancer Research. 7: 215–229 (2021).
Hummel, H. D., et al. “Bispecific antibodies for cancer therapy: An update.” Cancer Research. 81: 2751–2761 (2021).
Vitiello, A., & Medzhitov, R. “Universal cancer vaccines: A potential breakthrough?” Nature Immunology. 21: 131–140 (2020).
Andrews, M. C., et al. “Vaccination for cancer prevention in hereditary syndromes.” Cancer Prevention Research. 12: 411–420 (2019).
Gavi, the Vaccine Alliance. “CEPI and the Global Vaccine Development Initiative.” CEPI Annual Report (2021). https://www.gavi.org
McGrogan, B., et al. “Real-world evidence in cancer vaccines: Opportunities and challenges.” Journal of Immunotherapy Advances. 2: ltad030 (2020).
Eichler, H. G., et al. “Adaptive licensing: Taking the next step in the evolution of drug approval.” Clinical Pharmacology & Therapeutics. 91: 426–437 (2012).